A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Phase 3 Not yet recruiting 210 enrolled Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to see whether the Trilaciclib is safe and effective in slowing down the growth of bladder cancer in patients while taking chemoimmunotherapy.

Timeline

Start: 2025-10
Primary completion: 2027-04-15
Completion: 2029-04-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trilaciclib	Unknown	240 mg/m2	—
Background	Cisplatin	Other / unclassified	70 mg/m2	—
Background	Gemcitabine	Small molecule	1000 mg/m2	—
Background	Tislelizumab	Monoclonal antibody	200 mg	—

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Summary

Timeline

Drugs

Indications